Fernández-Quintela Alfredo, Carpéné Christian, Fernández Maialen, Aguirre Leixuri, Milton-Laskibar Iñaki, Contreras José, Portillo Maria P
Nutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Center, University of the Basque Country (UPV/EHU), Vitoria, Spain.
CIBERobn Physiopathology of Obesity and Nutrition, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
J Physiol Biochem. 2016 Aug;73(3):417-429. doi: 10.1007/s13105-016-0544-y. Epub 2016 Dec 15.
The prevalence of obesity has increased rapidly during recent years and has reached epidemic proportions. As a result, the scientific community is interested in active biomolecules which are naturally present in plants and foodstuffs and may be useful in body weight management. In recent years, polyphenols have made up one of the most frequently studied groups among these molecules. Numerous studies have been carried out on animals to analyse the potential anti-obesity effects of resveratrol, a non-flavonoid polyphenol, and a general consensus concerning the body-fat-lowering effect of this compound exists. By contrast, studies in humans have been few so far. Moreover, in these studies, the effectiveness of resveratrol is low. The aims of the present review are to summarize the results reported so far on this topic and to justify the differences observed between animals and humans. It seems that the reduced response to resveratrol in humans cannot be attributed to the use of lower doses in humans because the doses that induce body-fat-lowering effects in rodents are in the same range as those used in human studies. With regard to the experimental period length, treatments were longer in animal studies than in human studies. This can be one of the reasons contributing to the reduced responses observed in humans. Moreover, animals used in the reported studies are young while volunteers participating in human studies are adults, suggesting that resveratrol may be more efficient in young individuals. In addition to differences in the experimental designs, metabolic differences between animals and human cannot be discarded.
近年来,肥胖症的患病率迅速上升,已达到流行程度。因此,科学界对植物和食品中天然存在的、可能有助于体重管理的活性生物分子感兴趣。近年来,多酚类物质是这些分子中研究最为频繁的类别之一。已经对动物进行了大量研究,以分析非黄酮类多酚白藜芦醇的潜在抗肥胖作用,并且关于这种化合物降低体脂的作用已达成普遍共识。相比之下,迄今为止针对人类的研究较少。此外,在这些研究中,白藜芦醇的效果较低。本综述的目的是总结迄今为止关于该主题报道的结果,并解释在动物和人类之间观察到的差异。似乎人类对白藜芦醇反应降低不能归因于人类使用的剂量较低,因为在啮齿动物中诱导降低体脂作用的剂量与人类研究中使用的剂量范围相同。关于实验周期长度,动物研究中的治疗时间比人类研究中的更长。这可能是导致在人类中观察到反应降低的原因之一。此外,报道研究中使用的动物是幼体,而参与人类研究的志愿者是成年人,这表明白藜芦醇在年轻个体中可能更有效。除了实验设计的差异外,动物和人类之间的代谢差异也不能被忽视。